Cytosorbents Co. (NASDAQ:CTSO – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 2,050,000 shares, a growth of 27.3% from the April 15th total of 1,610,000 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily volume of 191,300 shares, the days-to-cover ratio is currently 10.7 days.
NASDAQ:CTSO traded up $0.09 during mid-day trading on Tuesday, hitting $2.22. 3,238 shares of the company traded hands, compared to its average volume of 294,798. The firm has a market cap of $96.70 million, a price-to-earnings ratio of -3.19 and a beta of 0.49. The stock’s fifty day moving average price is $2.75 and its 200-day moving average price is $3.83. Cytosorbents has a one year low of $1.78 and a one year high of $9.80.
Cytosorbents (NASDAQ:CTSO – Get Rating) last posted its earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). Cytosorbents had a negative return on equity of 44.65% and a negative net margin of 71.16%. During the same period in the previous year, the company earned ($0.10) earnings per share. As a group, equities research analysts expect that Cytosorbents will post -0.61 EPS for the current fiscal year.
A number of research analysts have issued reports on CTSO shares. B. Riley lowered their price objective on Cytosorbents from $7.00 to $6.00 in a research note on Wednesday, May 4th. StockNews.com assumed coverage on Cytosorbents in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Cytosorbents currently has a consensus rating of “Buy” and an average price target of $9.67.
Cytosorbents Company Profile (Get Rating)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.